BD Strikes $19B U.S. Manufacturing Deal With Trump Administration for Tariff Relief
BDX sits 43% above its 52-week low of $127.536.
Summary
BD has agreed to invest $19 billion in U.S. manufacturing over several years in exchange for relief from future tariffs. The deal includes $3 billion for expanding U.S. manufacturing, with over $1 billion earmarked for Nebraska, and a commitment to produce an additional five billion medical consumables annually, raising domestic supply to roughly 80%. The company will also domestically manufacture all U.S. needles using American-made steel. This follows President Trump's earlier announcement of the $3 billion investment and his threat to impose medical device tariffs by year-end. The agreement provides BD with tariff protection while aligning with administration pressure to onshore medical manufacturing. Financial impact is not yet quantified, pending final tariff policy scope and milestone achievement.
Updates
· Benzinga — BD shares rose 2.06% to $184.38 following the announcement.
- The tariff relief is specifically for "Section 232 tariffs" and applies "on specified products and materials".
- Tariff relief is provided "provided it meets agreed-upon operational milestones".
- The $19 billion investment encompasses "capital, operational, and supply chain enhancements".
At the time of this announcement, BDX was trading at $182.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $49.2B. The 52-week trading range was $127.54 to $193.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.